Repligen
RGEN
$181.13
+0.47%
Repligen Corporation is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, vaccines, and cell and gene therapies. The company holds a strong market position as a leading supplier of filtration, chromatography, and fluid management technologies, with a diversified customer base spanning biopharmaceutical companies and contract development and manufacturing organizations. The current investor narrative centers on the company's recovery from a post-pandemic slowdown, with recent quarterly results showing accelerating revenue growth and a robust rebound in bioprocessing demand. Additionally, the broader life sciences sector has seen increased M&A activity, as evidenced by Merck KGaA's acquisition offer for Bio-Techne, which has fueled optimism about Repligen's strategic value and growth prospects.…
RGEN
Repligen
$181.13
Related headlines
Investment Opinion: Should I buy RGEN Today?
Based on the analysis, Repligen is rated a Buy, supported by strong revenue acceleration, improving profitability, and a solid balance sheet. The consensus rating is Strong Buy with an average target of $185.70, implying 2.5% upside, but the high target of $220 suggests 21% upside if the company executes well. The thesis is that Repligen is a high-quality growth company in a recovering bioprocessing market, and its current valuation, while rich, is justified by its growth prospects.
Supporting evidence includes: (1) Q1 2026 revenue growth of 14.83% YoY, with sequential acceleration; (2) operating margin expansion from 3.9% to 9.3% YoY; (3) strong liquidity with $582.7M cash and $104.1M TTM free cash flow; and (4) a forward PE of 68.6x, which is high but reflects expected earnings growth of over 100% next year. The PS ratio of 12.5x is a premium to the sector average of 4.5x, but this is typical for a growth leader. The company's gross margin of 50.7% is healthy and supports its competitive position.
The biggest risks are valuation compression and growth deceleration. If revenue growth falls below 10% or margins deteriorate, the stock could de-rate significantly. This Buy would be downgraded to Hold if the forward PE exceeds 80x or if the company guides to slower growth. Conversely, it could be upgraded to a Strong Buy if the stock pulls back to below $150 while fundamentals remain intact. Overall, Repligen is fairly valued relative to its growth potential, but investors should be mindful of the high expectations embedded in the price.
Sign up to view all
RGEN 12-Month Price Forecast
The AI assessment is bullish on Repligen, driven by the company's strong operational recovery and favorable sector dynamics. The accelerating revenue growth and margin expansion provide tangible evidence of improving fundamentals, while the strong balance sheet offers a safety net. However, the high valuation (forward PE 68.6x) and modest analyst upside (2.5%) temper confidence, making the stance bullish but with medium confidence. To upgrade to high confidence, we would need to see sustained double-digit growth and margin improvement, along with a more attractive entry point. Conversely, a downgrade to neutral would occur if growth decelerates or if the stock's valuation becomes even more stretched.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Repligen's 12-month outlook, with a consensus price target around $185.70 and implied upside of +2.5% versus the current price.
Average Target
$185.70
0 analysts
Implied Upside
+2.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$145 - $220
Analyst target range
Repligen has coverage from 20 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.5). The average target price is $185.70, implying a modest upside of 2.5% from the current price of $181.13. The distribution is bullish, with no sell ratings and a majority of buys. The target price range is $145.00 to $220.00, with the low target suggesting a potential downside of 20% if growth disappoints, while the high target implies a 21% upside if the company executes on its growth plans. Recent ratings actions have been positive, with Benchmark upgrading from Hold to Buy in July 2026, and several firms maintaining Overweight ratings. The wide spread between low and high targets reflects uncertainty about the pace of recovery in bioprocessing demand, but the overall sentiment is constructive.
Bulls vs Bears: RGEN Investment Factors
Repligen presents a compelling growth story with accelerating revenue, improving margins, and a strong balance sheet, but the stock's valuation is stretched, trading at a significant premium to peers. The bull case is supported by tangible operational improvements and sector tailwinds, while the bear case hinges on the high expectations embedded in the price. Currently, the bull case has stronger evidence given the recent momentum and analyst optimism, but the key tension is whether the company can sustain double-digit growth to justify its forward PE of 68.6x. If growth decelerates or margins disappoint, the stock could face a de-rating, making the valuation the single most critical factor to watch.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 14.83% YoY to $194.3M, up from $169.2M in Q1 2025, marking the third consecutive quarter of sequential growth. This confirms a strong recovery from the 2024 trough and signals renewed bioprocessing demand.
- Expanding Operating Leverage: Operating margin improved to 9.3% in Q1 2026 from 3.9% a year ago, while gross margin expanded to 50.7% from 53.6% (though slightly down sequentially). This demonstrates the company's ability to convert revenue growth into profitability.
- Strong Balance Sheet and Liquidity: With a current ratio of 8.37, debt-to-equity of 0.33, and $582.7M in cash, Repligen has ample financial flexibility. Q1 2026 free cash flow of $23.3M and positive TTM FCF of $104.1M support continued investment in growth.
- Bullish Analyst Sentiment: 20 analysts rate the stock a Strong Buy (mean 1.5) with an average target of $185.70, implying 2.5% upside. The high target of $220 suggests 21% upside, and recent upgrades (e.g., Benchmark to Buy) reflect growing confidence.
Bearish
- Extremely High Valuation: Trailing PE is 188.3x and forward PE is 68.6x, implying earnings must more than double in the next year. PS ratio of 12.5x is 178% above the sector average of 4.5x, leaving little room for error.
- Modest Analyst Upside: The average analyst target of $185.70 is only 2.5% above the current price of $181.13, suggesting limited near-term upside. The low target of $145 implies a 20% downside if growth disappoints.
- Earnings Volatility and Low Margins: Net margin is just 6.6% (Q1 2026), and the company has a history of volatile earnings, including a -$33.9M net loss in Q4 2024. This makes the stock sensitive to any operational hiccup.
- High Expectations Embedded in Price: The stock trades near its 52-week high (96% of range) after a 51% 1-year gain, and the forward PE of 68.6x requires flawless execution. Any guidance miss could trigger a sharp correction.
RGEN Technical Analysis
Repligen's stock is in a strong uptrend, with a 1-year price change of +51.38% and a 6-month change of +33.50%. The current price of $181.13 is near the upper end of its 52-week range, sitting at approximately 96% of the range (calculated as (181.13 - 100.99) / (188.73 - 100.99) = 0.96). This positioning near the highs suggests strong momentum, though it also indicates the stock may be overextended in the short term.
Beta
1.01
1.01x market volatility
Max Drawdown
-40.3%
Largest decline past year
52-Week Range
$101-$189
Price range past year
Annual Return
+51.4%
Cumulative gain past year
| Period | RGEN Return | S&P 500 |
|---|---|---|
| 1m | +29.3% | +3.6% |
| 3m | +57.4% | +2.7% |
| 6m | +33.5% | +11.4% |
| 1y | +51.4% | +18.7% |
| ytd | +10.2% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RGEN Fundamental Analysis
Repligen's revenue trajectory is accelerating, with Q1 2026 revenue of $194.3 million, up 14.83% year-over-year, and sequential growth from $197.9 million in Q4 2025 (which was up from $188.8 million in Q3 2025). The multi-quarter trend shows a clear recovery from the 2024 trough, with revenue growing from $154.9 million in Q3 2024 to the current level. The growth is driven by strong demand for bioprocessing equipment, particularly in filtration, which accounts for about 55% of revenue. The company's profitability is improving, with net income of $8.3 million in Q1 2026, up from $5.8 million in Q1 2025, and gross margin expanding to 50.7% from 53.6% in the prior year quarter. Operating margin improved to 9.3% from 3.9% a year ago, indicating operational leverage. Repligen's balance sheet is solid, with a current ratio of 8.37 and a debt-to-equity ratio of 0.33, reflecting low leverage. The company generated $23.3 million in free cash flow in Q1 2026, and has $582.7 million in cash, providing ample liquidity for growth investments.
Quarterly Revenue
$194255000.0B
2026-03
Revenue YoY Growth
+14.8%
YoY Comparison
Gross Margin
50.7%
Latest Quarter
Free Cash Flow
$104112000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RGEN Overvalued?
Given that Repligen is profitable, the PE ratio is the primary valuation metric. The trailing PE is 188.3x, while the forward PE is 68.6x, indicating the market expects significant earnings growth. The gap between trailing and forward PE suggests that earnings are expected to more than double in the next year, which is a high bar. Compared to the industry average, Repligen trades at a premium, with a PS ratio of 12.5x versus the sector average of 4.5x, representing a 178% premium. This premium is justified by the company's strong growth and market position, but it also implies high expectations. Historically, the stock's PE has ranged from 45x to over 1000x, and the current trailing PE of 188x is above the historical median, indicating that the market is pricing in optimistic future growth.
PE
188.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 45x~196x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
56.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's high valuation, which leaves little margin for error. With a trailing PE of 188.3x and forward PE of 68.6x, any earnings miss could lead to a sharp multiple contraction. Additionally, net margin is only 6.6%, and the company has shown earnings volatility, including a net loss in Q4 2024. While the balance sheet is strong (debt-to-equity 0.33, current ratio 8.37), the reliance on continued growth to justify the valuation is a significant financial risk. The company's free cash flow is positive but modest relative to its market cap, and any increase in capital expenditures or acquisitions could strain liquidity.
Market and competitive risks include valuation compression risk, as the stock trades at a 178% premium to the sector on a PS basis. The life sciences tools market is competitive, with players like Danaher and Sartorius, and any technological disruption could erode Repligen's market share. Regulatory changes in biopharma manufacturing could also impact demand. The stock's beta of 1.012 indicates it moves in line with the market, but its high valuation makes it more sensitive to sector rotation. The recent M&A activity in the sector (e.g., Merck KGaA's offer for Bio-Techne) could either benefit Repligen as an acquisition target or increase competition if peers consolidate.
In a worst-case scenario, if bioprocessing demand slows again or the company fails to meet growth expectations, the stock could fall to its 52-week low of $100.99, representing a -44% decline from the current price of $181.13. This could be triggered by a combination of factors: a macroeconomic downturn reducing biopharma capex, a major product failure, or a loss of key customers. The historical max drawdown of -40.28% shows that such declines are possible. Investors should be prepared for significant volatility, as the stock's high beta and valuation amplify downside risks in adverse conditions.